IceCure Medical Ltd. (NASDAQ:ICCM) Receives Average Rating of "Buy" from Analysts

Key Points

• IceCure Medical Ltd. has received a consensus rating of "Buy" from four analysts, with price target estimates averaging $2.3850.
• The company's stock recently traded at $0.96 and has a market capitalization of $66.23 million, showing a significant drop from its 1-year high of $1.66.
• Despite reporting earnings per share of $0.06—higher than the consensus estimate—the company still recorded a negative net margin of 317.62%.

IceCure Medical Ltd. (NASDAQ:ICCM - Get Free Report) has earned a consensus rating of "Buy" from the four analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $2.3850.

A number of equities analysts have weighed in on the company. Zacks Research cut IceCure Medical from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Brookline Capital Management restated a "buy" rating on shares of IceCure Medical in a report on Wednesday, August 13th. Loop Capital set a $2.77 price target on IceCure Medical in a report on Wednesday, August 13th. Weiss Ratings restated a "sell (e+)" rating on shares of IceCure Medical in a report on Saturday, September 27th. Finally, HC Wainwright decreased their price target on IceCure Medical from $2.50 to $2.00 and set a "buy" rating for the company in a report on Friday, August 15th.

IceCure Medical Price Performance

ICCM stock traded down $0.03 during trading on Friday, hitting $0.96. The stock had a trading volume of 15,174,034 shares, compared to its average volume of 883,217. The company's 50 day moving average price is $0.99 and its two-hundred day moving average price is $1.05. IceCure Medical has a 1-year low of $0.48 and a 1-year high of $1.66. The stock has a market cap of $66.23 million, a price-to-earnings ratio of -6.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.88 and a current ratio of 1.18.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.12. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. The firm had revenue of $0.66 million during the quarter, compared to the consensus estimate of $0.90 million. On average, sell-side analysts forecast that IceCure Medical will post -0.28 EPS for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.